Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus
Status:
Terminated
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is the determine whether a new compound, called lapatinib, can be
effective in shrinking cancerous tumors of the esophagus that have recurred or spread
somewhere else in the body. They also want to determine the toxicity of this regimen.
Lapatinib blocks 2 receptors that sometimes are present on cancer cells (called epidermal
growth factor receptor, and the Erb B2 receptor). It is possible that blocking these
receptors may decrease the growth of the cancer cells.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center